Need a specific person's email?
Browse Genialis's employee directory (about 31 employees) and reveal verified emails free.
Genialis's most common email format is First@genialis.com (ex. John@genialis.com), used for 59% of genialis.com addresses. Genialis uses 4 email patterns.
| Format | Example | Share of genialis.com |
|---|---|---|
| First@genialis.comMost common | John@genialis.com | |
| First.Last@genialis.com | John.Doe@genialis.com | |
| Last@genialis.com | Doe@genialis.com | |
| FirstL@genialis.com | JohnD@genialis.com |
Browse Genialis's employee directory (about 31 employees) and reveal verified emails free.
Biotechnology ResearchMassachusetts, United States11-50 Employees
Genialis is a mid-sized biotechnology research company based in Boston, Massachusetts. It develops and validates clinically actionable biomarkers informed by ethnically diverse cancer datasets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. The company partners with pharmaceutical and diagnostics players to translate data into actionable insights that support clinical development and decision-making. In 2026, Genialis launched Genialis BioBridge to help translate clinical results from Chinese patient populations into biomarker-ready assets for Western trials and regulatory submissions. It has established collaborations with institutions and industry partners, including a 2025 collaboration with Debiopharm Group to develop a predictive biomarker for a WEE1-targeted therapy, and a 2025 collaboration with the Cleveland Clinic focused on AI-powered biomarkers for pancreatic cancer care. The organization has been recognized in industry awards, including Biomarker Discovery Platform of the Year at the BioTech Breakthrough Awards in 2025.
Most common format
First@genialis.com
Example: John@genialis.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.